Investor Relations
Founded in 2016, Stemnovate is on a mission to revolutionize drug discovery. Our pioneering approach harnesses cutting-edge technologies, including multi-omics, stem cells, microengineering, and data analytics. Multi-omics, a comprehensive analysis of various & omics& data such as genomics, proteomics, and metabolomics, allows us to gain a holistic understanding of diseases and potential treatments. This powerful combination positions us at the forefront of accelerating breakthroughs and rapidly translating innovations into clinical applications. We are dedicated to enhancing our understanding of diseases and expediting the journey to market for innovative treatments.
Dr Ruchi Sharma
(CEO & CSO)
Our CEO, a dynamic professional with profound expertise in science and entrepreneurship, is at the helm of Stemnovate. Her journey began as a veterinarian and led her to a doctorate in advanced genomics and stem cell research at the University of Edinburgh. She further distinguished herself at the University of Cambridge, where she concentrated on translating stem cells into impactful cell therapies.
Stemnovate Timeline
Vision
At Stemnovate, we are committed to shaping the future with our innovative integrated technology platform. This platform accelerates clinical translation and minimizes reliance on animal testing, inspiring a new era of ethical drug discovery. By reducing the need for animal testing, we are not only accelerating the drug discovery process but also upholding our commitment to ethical and humane research practices.
Mission
With millions still waiting for diagnoses and treatments, Stemnovate is laser-focused on expediting drug discovery. Our goal is to enhance the reliability of pharmaceutical innovations, promote inclusivity, and improve data capture-all while embracing increased automation. We believe in a future where no patient is left behind.
Impact
Stemnovate provides a state-of-the-art platform for rare mitochondrial diseases in children. Our patient-centric approach empowers parents, mitochondrial clinicians, and pharmaceutical companies to engage meaningfully with our advanced research platform, significantly speeding up the development of new treatments and breaking down global barriers. We proudly maintain a zero-animal-testing record, underscoring our unwavering commitment to ethical practices.
Investing in Stemnovate
Stemnovate has secured over £1 million in prestigious grants, including Innovate UK, NC3Rs, and EU grants. Additionally, we have attracted £1 million in angel investment through SEIS and EIS programs. As a knowledge-intensive organization, we continue to offer appealing EIS benefits to our investors. The company is poised for robust growth and promising returns on investment, with patented technology, multiple product offerings generating revenue and partnerships with leading pharmaceutical companies. Our customer base spans more than 10 countries, including the USA, France, Germany, Italy, Denmark, Switzerland, and the Netherlands.